11,336 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Purchased by Advantage Alpha Capital Partners LP

Advantage Alpha Capital Partners LP bought a new stake in shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 11,336 shares of the company’s stock, valued at approximately $510,000.

Several other hedge funds and other institutional investors have also recently modified their holdings of the business. Farallon Capital Management LLC grew its position in Protagonist Therapeutics by 1.8% in the 2nd quarter. Farallon Capital Management LLC now owns 5,840,773 shares of the company’s stock valued at $202,383,000 after acquiring an additional 101,800 shares during the last quarter. Vanguard Group Inc. grew its holdings in shares of Protagonist Therapeutics by 1.2% in the first quarter. Vanguard Group Inc. now owns 3,192,971 shares of the company’s stock worth $92,373,000 after purchasing an additional 39,055 shares during the last quarter. Pacer Advisors Inc. lifted its holdings in Protagonist Therapeutics by 405,061.2% during the 3rd quarter. Pacer Advisors Inc. now owns 1,734,090 shares of the company’s stock valued at $78,034,000 after buying an additional 1,733,662 shares in the last quarter. Perceptive Advisors LLC boosted its position in Protagonist Therapeutics by 27.6% in the 2nd quarter. Perceptive Advisors LLC now owns 1,268,735 shares of the company’s stock valued at $43,962,000 after buying an additional 274,412 shares during the period. Finally, Millennium Management LLC grew its stake in Protagonist Therapeutics by 2,135.6% in the 2nd quarter. Millennium Management LLC now owns 958,283 shares of the company’s stock worth $33,205,000 after acquiring an additional 915,418 shares in the last quarter. 98.63% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

PTGX has been the subject of several research analyst reports. Wedbush reaffirmed an “outperform” rating and set a $58.00 price target on shares of Protagonist Therapeutics in a research note on Tuesday, November 19th. JMP Securities dropped their price target on Protagonist Therapeutics from $45.00 to $43.00 and set a “market outperform” rating on the stock in a research report on Wednesday, August 7th. HC Wainwright restated a “buy” rating and issued a $50.00 price objective on shares of Protagonist Therapeutics in a report on Tuesday, November 19th. StockNews.com upgraded shares of Protagonist Therapeutics from a “hold” rating to a “buy” rating in a report on Thursday, August 8th. Finally, TD Cowen upgraded shares of Protagonist Therapeutics to a “strong-buy” rating in a report on Wednesday, September 25th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $53.57.

Insider Activity at Protagonist Therapeutics

In other news, Director William D. Waddill sold 8,000 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $45.00, for a total transaction of $360,000.00. Following the transaction, the director now owns 12,000 shares in the company, valued at $540,000. This represents a 40.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Arturo Md Molina sold 1,906 shares of Protagonist Therapeutics stock in a transaction that occurred on Friday, November 15th. The stock was sold at an average price of $40.98, for a total transaction of $78,107.88. Following the completion of the sale, the insider now owns 46,444 shares of the company’s stock, valued at $1,903,275.12. This trade represents a 3.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 24,109 shares of company stock valued at $1,069,999 over the last 90 days. Insiders own 5.40% of the company’s stock.

Protagonist Therapeutics Stock Performance

NASDAQ:PTGX opened at $44.83 on Wednesday. The company’s 50-day simple moving average is $45.24 and its 200-day simple moving average is $39.58. Protagonist Therapeutics, Inc. has a fifty-two week low of $16.80 and a fifty-two week high of $48.89. The stock has a market capitalization of $2.67 billion, a P/E ratio of 16.85 and a beta of 2.17.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.